Similar Papers

Paper Title
Journal
Date
Author
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Hidetomo Himuro ... Naoko Higashijima
Cancer Immunology, Immunotherapy | VOL. 72
Hidetomo Himuro, et. al.Hidetomo Himuro ... Naoko Higashijima
16 May 2023
Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
Yibo Fan ... Ti Wen
Annals of Surgical Oncology | VOL. 26
Yibo Fan, et. al.Yibo Fan ... Ti Wen
13 May 2019
Plasma cell-free RNA PD-L1 expression and survival with immune checkpoint inhibitor-based treatment in advanced non-small-cell lung cancer.
Paul R Walker ... Sriraksha Jayananda
Journal of Clinical Oncology | VOL. 41
Paul R Walker, et. al.Paul R Walker ... Sriraksha Jayananda
01 Jun 2023
Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice.
Myrna G Garcia ... Aravind Kancharla
Aging and Cancer | VOL. 3
Myrna G Garcia, et. al.Myrna G Garcia ... Aravind Kancharla
25 Feb 2022
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
A Perspective on the MARS2 Trial
Eric Lim ... Harvey Pass
Journal of Thoracic Oncology | VOL. -
Eric Lim, et. al.Eric Lim ... Harvey Pass
01 Jan 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Editorial Board
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
Afshin Dowlati ... Saiama N Waqar
Journal of Thoracic Oncology | VOL. -
Afshin Dowlati, et. al.Afshin Dowlati ... Saiama N Waqar
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.